Premium
Potential of nucleofected human MSCs for insulin secretion
Author(s) -
Kim Jae Hyung,
Shin KyooHo,
Li Tian Zhu,
Suh Hwal
Publication year - 2011
Publication title -
journal of tissue engineering and regenerative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.835
H-Index - 72
eISSN - 1932-7005
pISSN - 1932-6254
DOI - 10.1002/term.371
Subject(s) - nucleofection , mesenchymal stem cell , insulin , transfection , diabetes mellitus , cell therapy , stem cell , type 1 diabetes , flow cytometry , medicine , biology , cell culture , immunology , endocrinology , microbiology and biotechnology , genetics
The goal of this experiment was to generate insulin‐producing human mesenchymal stem cells (hMSCs) as a therapeutic source for type I diabetes mellitus, which is caused by insulin deficiency due to the destruction of islet β cells. In various trials for the treatment of type I diabetes, cell‐based therapy using adult stem cells is considered to be one of the most useful candidates for the treatment. In this experiment, a non‐viral method called nucleofection was used to transfect hMSCs with pEGFP‐C2 and furin‐cleavable human preproinsulin gene (hPPI) to produce insulin‐secreting cells as surrogate β cells. Transfection efficiency was determined using flow cytometry analysis. Expression and production of insulin were tested using RT–PCR and ELISA. The expression, production and maturation of insulin from the genetically engineered hMSCs showed an increase when compared with a non‐transfected control group. Insulin expression from hMSCs using nucleofection in this study has shown the potential for type I diabetes therapy. For further study, an evaluation for in vivo experiments and clinical applications must be supplemented. Copyright © 2010 John Wiley & Sons, Ltd.